Keywords: Genzyme, Sanofi, Eliglustat, Ph III, Gaucher disease

Genzyme's eliglustat meets endpoints in Ph III studies for Gaucher disease

Article | 18 February 2013

Print This

US biotech firm Genzyme, a subsidiary if French drug major Sanofi (Euronext: SAN) has released positive new data from two ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in